|Bid||4.96 x 3000|
|Ask||5.07 x 1100|
|Day's Range||4.94 - 5.08|
|52 Week Range||3.05 - 11.65|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 20, 2019 - Mar 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.75|
Basking Ridge, New Jersey, Jan. 07, 2019 -- Caladrius Biosciences to Participate in Upcoming January Conferences BASKING RIDGE, N.J. (January 7, 2019) – Caladrius Biosciences,.
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Basking Ridge, NJ, Nov. 09, 2018 -- Caladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare.
Development programs remain on track accompanied by continued strong fiscal management Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., Nov. 08,.
BASKING RIDGE, N.J. (November 8, 2018) – Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune disease, announces today the appointment of Ms. Cynthia Schwalm to its Board of Directors. “Cynthia brings extensive experience in leading and managing biopharmaceutical companies during transformative years of growth,” said David J. Mazzo, PhD, Chief Executive Officer of Caladrius.
Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will release financial results for the three and nine months ended September 30, 2018 after close of the U.S. financial markets on Thursday, November 8, 2018. The call will also be broadcast live on the Internet via the Company’s website at www.caladrius.com/investors/news-events. The webcast replay will be archived on the Company’s website for 90 days at www.caladrius.com.
If you’re interested in Caladrius Biosciences Inc (NASDAQ:CLBS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Caladrius Biosciences, Inc. (NASDAQ: CLBS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 4:30 PM Eastern ...
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a day of big gains for biotech stocks Sarepta Therapeutics and Caladrius Biosciences on Tuesday. Sarepta soared almost 37% on positive interim data on ...
For diabetes sufferers, it’s not just effective medications that are necessary, but effective self-management. The challenge with diabetes, both type 1 and type 2, is not necessarily that the medications we have available today are just not good enough. The problem is, the disease has to be managed constantly, from the moment you wake up […] The post For Diabetes Patients, Management Solutions Are As Critical As Medications appeared first on Market Exclusive.
Stock Monitor: Caladrius Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Mesoblast Ltd (NASDAQ: MESO ). If ...